Hodgkins

PeopleKeep Report Finds QSEHRA Provides Non-Profit Organizations Affordable Option for Offering Health Benefits

Retrieved on: 
Thursday, June 1, 2023

PeopleKeep , the leader in personalized benefits for small and midsize organizations, today announced a new national report showing qualified small employer health reimbursement arrangements (QSEHRAs) provide nonprofit organizations an affordable way to offer health benefits to their employees.

Key Points: 
  • PeopleKeep , the leader in personalized benefits for small and midsize organizations, today announced a new national report showing qualified small employer health reimbursement arrangements (QSEHRAs) provide nonprofit organizations an affordable way to offer health benefits to their employees.
  • According to a survey and data from nonprofit organizations that use QSEHRAs, before offering a plan, 67% of nonprofits didn’t provide any health insurance.
  • A QSEHRA is a formal, IRS-approved health benefit allowing small businesses with fewer than 50 full-time equivalent employees to offer a tax-free reimbursement to employees for their health insurance premiums and other qualifying health expenses.
  • Nonprofits that are new with QSEHRA benefits provide a monthly allowance of $420, whereas organizations with 3+ years of experience give almost $500 on average.

Controversial Monsanto Roundup Weed Killer Settlement Under Scrutiny

Retrieved on: 
Thursday, May 20, 2021

Among other things, the proposal would require healthy individuals who have already been exposed to Roundup to relinquish their right to sue if they are later diagnosed with non-Hodgkins lymphoma.

Key Points: 
  • Among other things, the proposal would require healthy individuals who have already been exposed to Roundup to relinquish their right to sue if they are later diagnosed with non-Hodgkins lymphoma.
  • "We will continue to fight for each cancer victim\'s right to a trial by jury and will opt out of this unfair proposal.
  • The largest and most diverse products liability law firm in the nation, Fears |Nachawatiwas rankedNo.
  • 1nationally in product liabilityfilings in federal courtover the last three years.

U.S. Federal Appeals Court Upholds $25m Monsanto Roundup Cancer Verdict

Retrieved on: 
Friday, May 14, 2021

Click here for details: https://bit.ly/3bramVi\nFriday\'s ruling stems from a 2019 jury verdict finding that plaintiff Edwin Hardeman developed non-Hodgkins lymphoma after exposure to Roundup.

Key Points: 
  • Click here for details: https://bit.ly/3bramVi\nFriday\'s ruling stems from a 2019 jury verdict finding that plaintiff Edwin Hardeman developed non-Hodgkins lymphoma after exposure to Roundup.
  • Among other things, the settlement would allow Bayer to continue selling Roundup but limit legal options for individuals diagnosed with cancer in the future.
  • A hearing on the settlement is set for May 19.\n"We now have a federal appellate court supporting evidence that Roundup causes cancer and that Bayer had a duty to warn consumers," Mr. Nachawati said.
  • "Shareholders need to know that these lawsuits will not stop until Bayer makes a meaningful settlement offer.

Treasures to transform lives are discovered in new captivating self-help memoir

Retrieved on: 
Wednesday, November 4, 2020

Standing beside her husband through a battle with non-Hodgkins lymphoma, Ibrahim shares the story of the ultimate challenge of being forced to remove their only child from life support.

Key Points: 
  • Standing beside her husband through a battle with non-Hodgkins lymphoma, Ibrahim shares the story of the ultimate challenge of being forced to remove their only child from life support.
  • Reviews repeatedly site the captivating effects of reading this book with claims of not being able to put the book down.
  • Filled with reflections and self-help opportunities, Ibrahim utilizes humor and humility while including specific methods to help readers cope with many of lifes crisis.
  • In order to fly, the butterfly must struggle to change, push through the cocoon and grow wings.

Tourmaline Partners Adds Senior Trader Joe Hodgkins in Sydney Office Amid Continued Asia-Pacific Growth

Retrieved on: 
Tuesday, February 11, 2020

Stamford, CT and Sydney, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Tourmaline Partners, LLC, one of the world's leading outsourced trading solutions firms, today announced the hire of Joe Hodgkins as a senior trader.

Key Points: 
  • Stamford, CT and Sydney, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Tourmaline Partners, LLC, one of the world's leading outsourced trading solutions firms, today announced the hire of Joe Hodgkins as a senior trader.
  • Tourmaline opened its Sydney office in January 2018 in response to increasing demand for outsourced and supplemental trading services in the Asia-Pacific (APAC) region.
  • Hodgkins comes to Tourmaline with extensive markets experience, spanning over 18 years of trading in Asia across senior buy- and sell-side roles.
  • Joe is a natural addition to our deeply experienced Australia team, said James Santo, Managing Director at Tourmaline in Sydney.

Hodgkin’s Lymphoma Drugs Market – Advances in Diagnostic Methods to Boost Growth through 2019-2023 | Technavio

Retrieved on: 
Monday, November 4, 2019

According to a recent Technavio report, the Hodgkins lymphoma drugs market is expected to grow by USD 1.24 billion during 2019-2023.

Key Points: 
  • According to a recent Technavio report, the Hodgkins lymphoma drugs market is expected to grow by USD 1.24 billion during 2019-2023.
  • Growth in the Hodgkins lymphoma drugs market can be attributed to many segments, one of which is the type segment comprising of targeted therapy and chemotherapy.
  • View the full release here: https://www.businesswire.com/news/home/20191104005652/en/
    Technavio has announced its latest market research report titled global hodgkins lymphoma drugs market 2019-2023.
  • As per Technavio, the Hodgkins lymphoma drugs market is forecast to grow at a CAGR of close to 16% by 2023.

Verastem Oncology to Announce Third Quarter 2019 Financial Results and Corporate Update on October 29, 2019

Retrieved on: 
Thursday, October 17, 2019

The live, listen-only webcast of the conference call can be accessed by visiting the investors section of the Company's website at www.verastem.com .

Key Points: 
  • The live, listen-only webcast of the conference call can be accessed by visiting the investors section of the Company's website at www.verastem.com .
  • A replay of the webcast will be archived on the Company's website for 90 days following the call.
  • Verastem Oncology (Nasdaq: VSTM) is a commercial biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer.
  • Our first FDA approved product is now available for the treatment of patients with certain types of indolent non-Hodgkins lymphoma (iNHL).

Brooke Besikof, 16, Actress, Cancer Survivor and Advocate, to Speak as Junior Ambassador on Behalf of CHLA Pediatric Cancer Research Initiative at TJ Martell Family Day at The Grove in Los Angeles

Retrieved on: 
Friday, October 4, 2019

When Brooke Besikof was 14 years old, she was diagnosed with Hodgkins Lymphoma, a rare cancer of the lymph system.

Key Points: 
  • When Brooke Besikof was 14 years old, she was diagnosed with Hodgkins Lymphoma, a rare cancer of the lymph system.
  • She has now become an advocate for other children battling the disease and has dedicated herself to raising research funds for pediatric cancer.
  • "Only four percent of research funding goes to pediatric cancer in the United States - we can do better than that.
  • Besikof will be representing CHLA as a speaker on Oct. 5,2019,at The Grove in Los Angeles for TJ Martell Family Day.

iBio and CC-Pharming Expand Business Collaboration in China

Retrieved on: 
Monday, August 26, 2019

According to industry reports , Rituximab is Roche Holding AGs second-biggest selling drug in China, with estimated annual sales of approximately 5 billion yuan ($708 million).

Key Points: 
  • According to industry reports , Rituximab is Roche Holding AGs second-biggest selling drug in China, with estimated annual sales of approximately 5 billion yuan ($708 million).
  • About 88,000 new patients are diagnosed with lymphoma in China each year, and 90% of them have non-Hodgkins lymphoma.
  • Under the terms of the license, iBio retains all rights to commercialize iBio technology-based products in markets outside of China.
  • iBio and CC-Pharming are currently evaluating the business feasibility of developing additional biopharmaceutical products for oncology, metabolic disorders, and fibrotic disease.

Verastem Oncology to Announce First Quarter 2019 Financial Results and Corporate Update on May 9, 2019

Retrieved on: 
Thursday, May 2, 2019

The live, listen-only webcast of the conference call can be accessed by visiting the investors section of the Company's website at www.verastem.com .

Key Points: 
  • The live, listen-only webcast of the conference call can be accessed by visiting the investors section of the Company's website at www.verastem.com .
  • A replay of the webcast will be archived on the Company's website for 90 days following the call.
  • Verastem Oncology (Nasdaq:VSTM) is a commercial biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer.
  • Our first FDA approved product is now available for the treatment of patients with certain types of indolent non-Hodgkins lymphoma (iNHL).